ScreenerHero

CGTXCognition Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · cogrx.com
0.9959USD+1.75%Mkt Cap: 94.70M $P/E: —

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central n…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap94.70M $
Enterprise Value57.55M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-23.49M $
Revenue/Share—
Last Price0.9959 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.35
PEG—
EV/EBITDA-1.57
EV/Revenue—
P/S—
P/B2.76
EPS (TTM)-0.17
EPS (Forward)-0.22
52W Range
0.550014% of range3.830
52W High3.830 USD
52W Low0.5500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-68.53%
ROA-48.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.59M $
CapEx (TTM)—
FCF Margin—
FCF Yield-25.29%
Net Debt-33.42M $
Net Debt/EBITDA0.91
Balance Sheet
Debt/Equity0.02
Current Ratio7.03
Quick Ratio6.78
Book Value/Sh0.3470 USD
Cash/Share0.3580 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.333 USD
Upside (mean)+234.7%
Target Range3.000 USD – 4.000 USD
$3.000+234.7% to mean$4.000
# Analysts3
Ownership
Shares Out.95.09M
Float87.42M
Insiders1.29%
Institutions23.79%
Short Interest
Short Ratio7.8d
Short % Float10.13%
Short % Out.9.39%
Shares Short8.93M
Short (prev mo.)7.07M
Technical
SMA 501.079 (-7.7%)
SMA 2001.226 (-18.8%)
Beta1.78
S&P 52W Chg18.16%
Avg Vol (30d)775.08K
Avg Vol (10d)630.03K
Technical Indicators
RSI (14)47.4
MACD-0.0124
MACD Signal-0.0216
MACD Hist.+0.0093
BB Upper1.099 USD
BB Middle0.9797 USD
BB Lower0.8603 USD
BB Width24.37%
ATR (14)0.0716 USD
Vol Ratio (20d)0.58x